Andrea Pirzkall

TL;DR: Evidence of a correlation between decreases in CTC counts and radiographic response by either FDG-PET or RECIST in patients with advanced NSCLC is provided and a potential role for using CTC decreases as an early indication of response to therapy and ctDNA for real-time assessment of mutation status from blood is suggested.

TL;DR: The data suggests that molecular characterization from captured C TCs is possible and can potentially provide real-time information on biomarker status, and limitations exist from a purely EpCAM based capture system and addition of antibodies to mesenchymal markers could further improve CTC capture efficiency to enable routine biomarker analysis from CTCs.

TL;DR: The combination of navoximod and atezolizumab demonstrated acceptable safety, tolerability, and pharmacokinetics for patients with advanced cancer and demonstrated a linear pharmacokinetic profile.

TL;DR: Early (d14) FDG-PET PMR is associated with improved PFS and OS, even in the absence of subsequent Response Evaluation Criteria in Solid Tumors response, and these data support inclusion of FDg-PET imaging in clinical trials testing novel targeted therapies, particularly those with anticipated cytostatic effects.

TL;DR: Navoximod was well-tolerated at doses up to 800 mg BID decreasing plasma kynurenine levels consistent with its half-life and exhibited dose-proportional increases in exposure supportive of BID dosing.